Compare Stocks

→ BREAKING – Pentagon to Spend $20 Billion on “Distributed AI” (From Behind the Markets) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACST Acasti Pharma	$2.88 +1.4%	$3.26	$1.72 ▼ $3.84	$27.07M	1.55	24,836 shs	624 shs
CTST CannTrust	C$0.64	C$0.64	C$0.38 ▼ C$8.17	C$90.27M	N/A	N/A	N/A
HOOK Hookipa Pharma	$0.80 -3.1%	$0.78	$0.41 ▼ $2.05	$79.31M	0.92	738,319 shs	317,000 shs
SNDX Syndax Pharmaceuticals	$22.15 -4.4%	$22.50	$11.22 ▼ $25.34	$1.88B	1.01	1.11 million shs	431,599 shs

7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACST Acasti Pharma	-0.68%	+5.40%	-13.82%	+24.15%	+6.16%
CTST CannTrust	0.00%	0.00%	0.00%	0.00%	0.00%
HOOK Hookipa Pharma	-6.05%	-6.80%	+9.78%	+22.70%	-46.65%
SNDX Syndax Pharmaceuticals	+3.02%	+9.70%	+1.27%	+4.04%	+14.24%

“Crash Insurance” For Your Retirement (Ad)

When it comes to retirement, everyone fears one thing… Outliving their retirement savings. You'll discover conservative, beginner-friendly options strategies which could help to cash flow your stock portfolio.

Click here to register for free.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACST Acasti Pharma	1.9052 of 5 stars	3.5	3.0	0.0	0.0	0.6	0.8	1.3
CTST CannTrust	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
HOOK Hookipa Pharma	2.998 of 5 stars	3.5	3.0	0.0	0.0	3.0	1.7	1.3
SNDX Syndax Pharmaceuticals	3.2005 of 5 stars	3.5	2.0	0.0	4.4	0.6	0.0	0.6

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACST Acasti Pharma	3.00	Buy	$6.00	108.33% Upside
CTST CannTrust	N/A	N/A	N/A	N/A
HOOK Hookipa Pharma	3.00	Buy	$4.67	482.24% Upside
SNDX Syndax Pharmaceuticals	2.90	Moderate Buy	$34.42	55.38% Upside

Current Analyst Ratings

Latest ACST, SNDX, CTST, and HOOK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/26/2024	HOOK Hookipa Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$6.50 ➝ $5.00
4/26/2024	SNDX Syndax Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$41.00
3/27/2024	SNDX Syndax Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$41.00
3/25/2024	HOOK Hookipa Pharma	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$5.00
3/25/2024	HOOK Hookipa Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.50
3/20/2024	SNDX Syndax Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$31.00 ➝ $34.00
2/28/2024	SNDX Syndax Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$41.00

(Data available from 5/8/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACST Acasti Pharma	N/A	N/A	N/A	N/A	$9.14 per share	N/A
CTST CannTrust	C$35.22M	2.56	N/A	N/A	N/A	∞
HOOK Hookipa Pharma	$20.13M	3.94	N/A	N/A	$0.91 per share	0.88
SNDX Syndax Pharmaceuticals	$139.71M	13.47	N/A	N/A	$6.53 per share	3.39

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACST Acasti Pharma	-$42.43M	-$5.08	N/A	N/A	N/A	N/A	-13.18%	-11.32%	6/28/2024 (Estimated)
CTST CannTrust	-C$10.46M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
HOOK Hookipa Pharma	-$81.58M	-$0.88	N/A	N/A	N/A	-405.28%	-72.30%	-40.51%	5/9/2024 (Confirmed)
SNDX Syndax Pharmaceuticals	-$209.36M	-$2.96	N/A	N/A	N/A	N/A	-47.88%	-44.00%	5/8/2024 (Confirmed)

Latest ACST, SNDX, CTST, and HOOK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/9/2024	N/A	HOOK Hookipa Pharma	-$0.12	N/A	+$0.12	N/A	N/A	N/A
5/8/2024	N/A	SNDX Syndax Pharmaceuticals	-$0.96	-$0.85	+$0.11	N/A	N/A	N/A
3/22/2024	Q4 2023	HOOK Hookipa Pharma	-$0.20	-$0.11	+$0.09	N/A	$3.60 million	$7.41 million
2/27/2024	Q4 2023	SNDX Syndax Pharmaceuticals	-$0.99	-$1.00	-$0.01	-$1.00	N/A	N/A
2/12/2024	12/31/2023	ACST Acasti Pharma	-$0.23	-$0.21	+$0.02	-$0.21	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACST Acasti Pharma	N/A	N/A	N/A	N/A	N/A
CTST CannTrust	N/A	N/A	N/A	N/A	N/A
HOOK Hookipa Pharma	N/A	N/A	N/A	N/A	N/A
SNDX Syndax Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACST Acasti Pharma	N/A	15.19	15.19
CTST CannTrust	N/A	N/A	N/A
HOOK Hookipa Pharma	N/A	3.50	3.50
SNDX Syndax Pharmaceuticals	N/A	10.00	10.00

Ownership

Institutional Ownership

Company	Institutional Ownership
ACST Acasti Pharma	6.08%
CTST CannTrust	0.03%
HOOK Hookipa Pharma	63.88%
SNDX Syndax Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
ACST Acasti Pharma	13.51%
CTST CannTrust	N/A
HOOK Hookipa Pharma	4.60%
SNDX Syndax Pharmaceuticals	4.10%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ACST Acasti Pharma	32	9.40 million	8.13 million	Not Optionable
CTST CannTrust	576	141.49 million	N/A	Optionable
HOOK Hookipa Pharma	56	98.95 million	94.40 million	Optionable
SNDX Syndax Pharmaceuticals	184	84.96 million	81.48 million	Optionable

ACST, SNDX, CTST, and HOOK Headlines

Source	Headline
	Syndax Pharmaceuticals, Inc.: Syndax Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update finanznachrichten.de - May 8 at 9:59 AM
	Syndax: Q1 Earnings Snapshot timesunion.com - May 8 at 9:58 AM
	Syndax Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update prnewswire.com - May 8 at 7:06 AM
	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) prnewswire.com - May 3 at 4:05 PM
	Syndax Pharmaceuticals (SNDX) Scheduled to Post Earnings on Wednesday marketbeat.com - May 2 at 10:00 AM
	Syndax to Announce First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024 prnewswire.com - May 1 at 7:00 AM
	Jennison Associates LLC Sells 2,296,893 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) marketbeat.com - April 28 at 5:47 AM
	Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Rating Reaffirmed by HC Wainwright americanbankingnews.com - April 28 at 3:30 AM
	Buy Rating Reaffirmed for Syndax Pharmaceuticals on Strong Drug Pipeline and Strategic Partnerships markets.businessinsider.com - April 26 at 5:05 PM
	Syndax Pharmaceuticals' (SNDX) "Buy" Rating Reaffirmed at HC Wainwright marketbeat.com - April 26 at 8:24 AM
	Syndax Pharmaceuticals gets grant for inhibitors of menin-mll interaction for cancer treatment pharmaceutical-technology.com - April 15 at 1:51 PM
	Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum finance.yahoo.com - April 10 at 7:46 PM
	Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum prnewswire.com - April 10 at 4:05 PM
	Analysts Are Bullish on Top Healthcare Stocks: Syndax Pharmaceuticals (SNDX), Legend Biotech (LEGN) markets.businessinsider.com - April 8 at 11:51 PM
	Buy Rating Affirmed for Syndax Pharmaceuticals Amidst Strong Clinical Results and Strategic Growth Prospects markets.businessinsider.com - April 8 at 6:50 PM
$Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session$	Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session prnewswire.com - April 8 at 7:00 AM
	Syndax Pharmaceuticals, Inc.: Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) finanznachrichten.de - April 6 at 8:34 AM
	Crinetics Pharmaceuticals gains amid pitch at Sohn charity conference (update) msn.com - April 3 at 1:44 PM
	Syndax completes enrollment in AUGMENT-101 pivotal trial cohort of patients with r/r mNPM1 acute myeloid leukaemia pharmabiz.com - March 31 at 4:16 AM
	20 European Cities with Highest Weed Consumption msn.com - March 29 at 7:06 AM
	This longevity company is letting you check the ‘credit score’ for your health. Here are my surprising results and biological age msn.com - March 29 at 2:06 AM
	Syndax (SNDX) Gets FDA Priority Tag for Leukemia Drug NDA msn.com - March 28 at 11:04 AM
$Syndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia$	Syndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia finance.yahoo.com - March 28 at 11:04 AM
	Syndax (SNDX) Gets FDA Priority Tag for Leukemia Drug NDA zacks.com - March 28 at 10:56 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Acasti Pharma

NASDAQ:ACST

Acasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada.

CannTrust

NYSE:CTST

CannTrust Holdings Inc. produces and sells medical and recreational cannabis in Canada. It sells dried cannabis and cannabis extracts to the medical patients. CannTrust Holdings Inc. was incorporated in 2015 and is headquartered in Vaughan, Canada.

Hookipa Pharma

NASDAQ:HOOK

HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.

Syndax Pharmaceuticals

NASDAQ:SNDX

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial